A Study of MK-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma
(MK-6482-005)
Research Question:
Does the drug MK-6482 work better than the drug everolimus in helping patients survive
solid tumors?
Basic Study Information
Purpose:
The primary objective of this study is to compare MK-6482 to everolimus with respect
to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors
Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR)
and to compare everolimus with respect to overall survival (OS). The hypothesis is
that MK-6482 is superior to everolimus with respect to PFS and OS.
Location: University of Rochester Medical Center
Study Reference #: IGUK19181
Lead Researcher (Principal Investigator)
Lead Researcher:
Deepak Sahasrabudhe, MD
Study Contact Information
Study Coordinator: Park Bogan
Phone: (585) 276-4415
Email: park_bogan@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search